Affiliation: Harvard University
Country: USA


  1. Hodi F, Chiarion Sileni V, Gonzalez R, Grob J, Rutkowski P, Cowey C, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480-1492 pubmed publisher
    ..The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. Bristol-Myers Squibb. ..
  2. Liu S, Camidge D, Gettinger S, Giaccone G, Heist R, Hodi F, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018;101:114-122 pubmed publisher
    ..Atezolizumab with chemotherapy was well tolerated with encouraging efficacy, though the analysis was limited by small numbers. NSCLC chemotherapy combination studies are ongoing. CLINICALTRIALS. NCT01633970. ..
  3. Subrahmanyam P, Dong Z, Gusenleitner D, Giobbie Hurder A, Severgnini M, Zhou J, et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer. 2018;6:18 pubmed publisher
    ..These functionally active NK cell subsets likely play a critical role in the anti-tumor response triggered by anti-PD-1. ..
  4. Zhou J, Gupta M, Wu X, Yoon C, Giobbie Hurder A, Hodi F. Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma. Cancer Immunol Res. 2015;3:59-67 pubmed publisher
    ..These results support the continued development of ATP6S1 as a biomarker and therapeutic target. ..
  5. Carvajal R, Lawrence D, Weber J, Gajewski T, Gonzalez R, Lutzky J, et al. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015;21:2289-96 pubmed publisher
    ..Nilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy. The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited. ..
  6. Ott P, Hodi F. The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chin Clin Oncol. 2013;2:7 pubmed publisher
  7. request reprint
    Hodi F, Granter S, Antin J. Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005;5:7 pubmed
  8. Weber J, Gibney G, Sullivan R, Sosman J, Slingluff C, Lawrence D, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17:943-955 pubmed publisher
    ..Nivolumab followed by ipilimumab appears to be a more clinically beneficial option compared with the reverse sequence, albeit with a higher frequency of adverse events. Bristol-Myers Squibb. ..
  9. Hodi F, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-42 pubmed publisher
    ..These findings provide a basis for further investigating the dual roles of angiogenic factors in blood vessel formation and immune regulation, as well as future combinations of antiangiogenesis agents and immune checkpoint blockade. ..

More Information


  1. Hodi F, O Day S, McDermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23 pubmed publisher
    ..Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; number, NCT00094653.) ..
  2. Hodi F, Hwu W, Kefford R, Weber J, Daud A, Hamid O, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016;34:1510-7 pubmed publisher
    ..1 might prevent premature cessation of treatment. ..
  3. Wu X, Giobbie Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, et al. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunol Res. 2016;4:858-868 pubmed
    ..IL1?, TNF?, and CXCL10, together with VEGF neutralization, contribute to Ipi-Bev-induced melanoma immune recognition. Cancer Immunol Res; 4(10); 858-68. ©2016 AACR. ..
  4. Hodi F, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558-1568 pubmed publisher
    ..The results suggest encouraging survival outcomes with immunotherapy in this population of patients. Bristol-Myers Squibb. ..
  5. Wu X, Giobbie Hurder A, Liao X, Connelly C, Connolly E, Li J, et al. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res. 2017;5:17-28 pubmed publisher
    ..Targeting ANGPT2 provides a rational combinatorial approach to improve the efficacy of immune therapy. Cancer Immunol Res; 5(1); 17-28. ©2016 AACR. ..
  6. Wu X, Li J, Connolly E, Liao X, Ouyang J, Giobbie Hurder A, et al. Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunol Res. 2017;5:446-454 pubmed publisher
    ..Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade. Cancer Immunol Res; 5(6); 446-54. ©2017 AACR. ..
  7. Zhou J, Mahoney K, Giobbie Hurder A, Zhao F, Lee S, Liao X, et al. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017;5:480-492 pubmed publisher
    ..Circulating sPD-L1 is a prognostic biomarker that may predict outcomes for subgroups of patients receiving checkpoint inhibitors. Cancer Immunol Res; 5(6); 480-92. ©2017 AACR. ..
  8. Hodi F, Oble D, Drappatz J, Velazquez E, Ramaiya N, Ramakrishna N, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5:557-61 pubmed publisher
    ..The patient was treated with ipilimumab on a compassionate-use program and dexamethasone, celecoxib, and levetiracetam to treat the symptoms and seizures. Postoperative stereotactic radiosurgery was initiated. ..